Results 181 to 190 of about 7,789 (204)

Upadacitinib

Reactions Weekly
  +35 more sources

Upadacitinib

Reactions Weekly, 2023
  +12 more sources

Upadacitinib: First Approval

Drugs, 2019
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of ...
Sean, Duggan, Susan J, Keam
openaire   +2 more sources

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Lancet, The, 2022
Julian Panes, Edward V Loftus, Remo Panaccione   +2 more
exaly  

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

New England Journal of Medicine, 2021
Marina Magrey, Joseph F Merola, Kishimoto Mitsumasa   +2 more
exaly  

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
Kristian Reich, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet, The, 2021
Andrew Blauvelt, D Thaçi, Chia Yu Chu
exaly  

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

New England Journal of Medicine, 2020
Jeffrey Enejosa, Boulos Haraoui, Maureen Rischmueller   +2 more
exaly